Sordi V, Pellegrini S, Krampera M, Marchetti P, Pessina A, Ciardelli G, Fadini G, Pintus C, Pantè G, Piemonti L
Diabetes Research Institute (DRI) - IRCCS San Raffaele Scientific Institute, Milan, Italy.
Stem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, Italy.
Nutr Metab Cardiovasc Dis. 2017 Jul;27(7):583-600. doi: 10.1016/j.numecd.2017.02.004. Epub 2017 Feb 21.
The advancement of knowledge in the field of regenerative medicine is increasing the therapeutic expectations of patients and clinicians on cell therapy approaches. Within these, stem cell therapies are often evoked as a possible therapeutic option for diabetes, already ongoing or possible in the near future.
The purpose of this document is to make a point of the situation on existing knowledge and therapies with stem cells to treat patients with diabetes by focusing on some of the aspects that most frequently raise curiosity and discussion in clinical practice and in the interaction with the patient. In fact, at present there are no clinically approved treatments based on the use of stem cells for the treatment of diabetes, but several therapeutic approaches have already been evaluated or are being evaluated in clinical trials.
It is possible to identify three large potential application fields: 1) the reconstruction of the β cell mass; 2) the immunomodulation in type 1 diabetes (T1D); 3) the treatment of complications. In this study we will limit the discussion to approaches that have the potential for clinical translation, deliberately omitting aspects of basic biology and preclinical data. Also, we intentionally omit the treatment of the complications that will be the subject of a future document. Finally, an overview of the Italian situation regarding the storage of cord blood cells for the therapy of diabetes will be given.
再生医学领域知识的进步提高了患者和临床医生对细胞治疗方法的治疗期望。其中，干细胞疗法经常被认为是治疗糖尿病的一种可能的治疗选择，无论是目前正在进行的还是在不久的将来可能开展的治疗。
本文的目的是通过关注临床实践以及与患者互动中最常引发好奇和讨论的一些方面，来阐述利用干细胞治疗糖尿病患者的现有知识和疗法的情况。事实上，目前尚无基于使用干细胞治疗糖尿病的临床批准疗法，但已有几种治疗方法在临床试验中得到评估或正在接受评估。
可以确定三个大的潜在应用领域：1）β细胞团的重建；2）1型糖尿病（T1D）中的免疫调节；3）并发症的治疗。在本研究中，我们将讨论局限于有可能转化为临床应用的方法，有意省略基础生物学和临床前数据的相关方面。此外，我们有意省略并发症的治疗内容，这将是未来一篇文章的主题。最后，将概述意大利在储存用于糖尿病治疗的脐血细胞方面的情况。
